Get the Stockscreener App
42.11
1.98%
-0.85
Pre-market:
42.39
0.28
+0.66%
Qiagen Nv stock is traded at $42.11, with a volume of 2.56M.
It is down -1.98% in the last 24 hours and up +0.31% over the past month.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
See More
Previous Close:
$42.96
Open:
$42.96
24h Volume:
2.56M
Relative Volume:
1.95
Market Cap:
$9.11B
Revenue:
$1.98B
Net Income/Loss:
$83.59M
P/E Ratio:
112.59
EPS:
0.374
Net Cash Flow:
$502.31M
1W Performance:
-0.14%
1M Performance:
+0.31%
6M Performance:
-3.96%
1Y Performance:
-7.65%
1-Day Range:
$42.03
$43.05
1-Week Range:
$41.73
$43.26
52-Week Range:
$37.74
$49.30
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
42.11 | 9.11B | 1.98B | 83.59M | 502.31M | 0.374 |
|
TMO
Thermo Fisher Scientific Inc
|
428.95 | 153.65B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
196.61 | 136.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
509.13 | 38.10B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
115.42 | 30.00B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
150.68 | 25.29B | 15.50B | 1.33B | 2.16B | 7.34 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-04-25 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-06-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-10-24 | Upgrade | Jefferies | Hold → Buy |
| Oct-17-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jun-27-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Dec-07-23 | Upgrade | Goldman | Neutral → Buy |
| Sep-12-23 | Initiated | Robert W. Baird | Outperform |
| May-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-18-22 | Upgrade | DZ Bank | Hold → Buy |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Oct-14-21 | Initiated | Redburn | Buy |
| Jul-14-21 | Downgrade | Kepler | Buy → Hold |
| Jun-03-21 | Initiated | Goldman | Neutral |
| Oct-06-20 | Resumed | BofA Securities | Buy |
| Sep-28-20 | Upgrade | Kepler | Hold → Buy |
| Aug-24-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Aug-17-20 | Upgrade | Berenberg | Hold → Buy |
| Aug-14-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-14-20 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-04-20 | Downgrade | Berenberg | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Dec-26-19 | Resumed | BofA/Merrill | Underperform |
| Nov-15-19 | Initiated | Stifel | Hold |
| Nov-14-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-14-19 | Upgrade | JP Morgan | Underweight → Overweight |
| Nov-14-19 | Upgrade | Kepler | Reduce → Hold |
| Oct-17-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-09-19 | Downgrade | Kepler | Hold → Reduce |
| Oct-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-08-19 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Qiagen Nv Stock (QGEN) Latest News
QIAGEN Stock Gains Following the Acquisition of Genoox - Zacks Investment Research
Qiagen Releases Q1 2025 Financial Report Highlighting Asset Decline - TipRanks
PTA-CMS: QIAGEN N.V.: Release of a capital market information - TradingView
Qiagen Acquires Genoox for $70 Million - marketscreener.com
QIAGEN acquires AI-powered software, Genoox - MSN
QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software - 01net
Qiagen (QGEN) Expands Genomic Capabilities with Genoox Acquisiti - GuruFocus
QIAGEN acquires Genoox to enhance genetic data analysis By Investing.com - Investing.com India
QIAGEN acquires Genoox to enhance genetic data analysis - Investing.com
Qiagen Acquires Genoox For $70 Million Plus $10 Million In Milestones - marketscreener.com
Analysts Are Updating Their Qiagen N.V. (NYSE:QGEN) Estimates After Its First-Quarter Results - simplywall.st
Is Qiagen (NYSE:QGEN) A Risky Investment? - simplywall.st
The Qiagen N.V. (NYSE:QGEN) First-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance
Qiagen N.V. (NYSE:QGEN) Q1 2025 Earnings Call Transcript - Insider Monkey
QIAGEN Reports Strong Q1 2025 Results and Plans Dividend Initiation - TipRanks
QIAGEN NV : UBS sticks Neutral - marketscreener.com
QIAGEN Reports Strong Q1 2025 Earnings - TipRanks
Qiagen: Good start to 2025 - marketscreener.com
Tissue Diagnostics Market to Reach $12.4 Billion by 2029, Growing at 7.0% CAGR - GlobeNewswire Inc.
QGEN Q1 Earnings and Revenues Top, Operating Margin Expands, Stock Up - TradingView
QIAGEN NV : Gets a Buy rating from Deutsche Bank - marketscreener.com
Qiagen: Q1 Earnings Snapshot - Norwalk Hour
QiagenH. Rusckowski To Succeed Lawrence A. Rosen As Chairman Of Supervisory Board Following AGM - marketscreener.com
QIAGEN announces plans for transition in leadership of Supervisory Board - BioSpace
Qiagen N : QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase - marketscreener.com
Qiagen N : QIAGEN announces plans for transition in leadership of Supervisory Board - marketscreener.com
QIAGEN announces plans for transition in leadership of Superviso - GuruFocus
QIAGEN (QGEN) Surpasses Q1 Revenue Forecasts, Highlights Strateg - GuruFocus
Stephen Rusckowski to Take Over as Chairman at Qiagen (QGEN) | Q - GuruFocus
Here's What Key Metrics Tell Us About Qiagen (QGEN) Q1 Earnings - Yahoo Finance
Qiagen NV reports results for the quarter ended March 31Earnings Summary - TradingView
QIAGEN delivers solid Q1 2025 results exceeding outlook; will se - GuruFocus
Qiagen (QGEN) Q1 Earnings and Revenues Surpass Estimates - Yahoo Finance
Qiagen board to elect Rusckowski chairman - TipRanks
Qiagen Q1 Adjusted Earnings, Revenue Rise; New $500 Million Stock Buyback Planned - marketscreener.com
QIAGEN (QGEN) Surpasses Q1 Revenue Forecasts, Highlights Strategic Growth | QGEN Stock News - GuruFocus
Stephen Rusckowski to Take Over as Chairman at Qiagen (QGEN) | QGEN Stock News - GuruFocus
Qiagen (QGEN) Announces Supervisory Board Transition - StreetInsider
QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase - Business Wire
QIAGEN to propose annual cash dividend for shareholder vote By Investing.com - Investing.com South Africa
QIAGEN to Propose Initiation of Annual Cash Dividend for Shareho - GuruFocus
Qiagen N : QIAGEN to propose initiation of annual cash dividend for shareholder approval at Annual General Meeting - marketscreener.com
Qiagen Plans to Initiate Dividend Payments - marketscreener.com
Qiagen NV (QGEN) Q1 2025 Earnings Report Preview: What To Expect - Yahoo Finance
QIAGEN to propose annual cash dividend for shareholder vote - Investing.com Australia
QIAGEN to Propose Initiation of Annual Cash Dividend for Shareholder Approval at Annual General Meeting | QGEN Stock News - GuruFocus
Qiagen N.V. Proposes Initiation of Annual Cash Dividend, Payable on July 10, 2025 - marketscreener.com
Qiagen To Propose Initiation Of Annual Cash Dividend At AGM - marketscreener.com
Qiagen Q1 2025 Earnings Call Transcript - MarketBeat
QIAGEN publishes 2023 sustainability report, highlighting progress on ESG goals and commitment to sustainable growth - ADVFN
Stay Ahead of the Game With Qiagen (QGEN) Q1 Earnings: Wall Street's Insights on Key Metrics - Yahoo Finance
Qiagen Nv Stock (QGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):